Hormonal
Intermittent hypoxia causes insulin resistance and Type 2 Diabetes by increasing ROS in pancreatic beta cells via HIF-1α, leading to hypersecretion of insulin and eventual beta-cell dysfunction.
Sleep apnea doesn't just affect your heart; it stresses your pancreas. The repeated oxygen drops trigger a response (HIF-1/ROS) that forces your beta cells to overwork and secrete too much insulin, leading to insulin resistance and Type 2 Diabetes. Treating your sleep apnea is essential to protect your metabolic health, not just your blood pressure.
IH-treated mice manifest elevated basal plasma insulin levels and insulin resistance... ROS levels are elevated in pancreatic β cells of IH-treated mice, and antioxidant treatment blocks the elevated insulin secretion and normalizes the HOMA index.
Why this rating
Strong rodent model evidence linking IH to insulin resistance and beta-cell dysfunction; human data is correlational.
Source
Hypoxia-inducible factors and obstructive sleep apnea
Nanduri R. Prabhakar et al. · Journal of Clinical Investigation · 2020
DOI 10.1172/jci137560
More from this paper
- Intermittent hypoxia (IH) characteristic of obstructive sleep apnea causes hypertension by dysregulating Hypoxia-Inducible Factors (HIF-1α and HIF-2α), which increases reactive oxygen species (ROS) to activate the sympathetic nervous system and impair baroreflex function.Good
- Intermittent hypoxia causes cognitive decline and memory impairment by increasing ROS in the hippocampus via HIF-1α, which downregulates NMDA receptors and disrupts synaptic plasticity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →